论文部分内容阅读
目的探讨氨磺必利治疗儿童少年期精神分裂症的临床疗效。方法选取2015年8月—2016年10月于晋江市疗养院精神科收治的儿童少年期精神分裂症患儿60例,随机将患儿分为奥氮平组与氨磺必利组,各30例。奥氮平组患儿予以口服奥氮平治疗,氨磺必利组予以口服氨磺必利治疗,两组患儿均连续治疗8周。比较两组患儿临床疗效、阳性和阴性症状量表(PANSS)评分(阴性症状、阳性症状、一般精神病理评分及总分)、临床总体印象量表-疾病严重程度(CGI-SI)总分、药物不良反应量表(TESS)评分及不良反应发生率。结果氨磺必利组患儿治疗总有效率为96.67%,高于奥氮平组的73.33%(P<0.05)。干预前两组患者阴性症状、阳性症状、一般精神病理评分及总分,CGI-SI总分比较,差异无统计学意义(P>0.05);干预后氨磺必利组阴性症状、阳性症状、一般精神病理评分及总分,CGI-SI总分低于奥氮平组(P<0.05)。氨磺必利组患儿TESS评分为(0.51±0.12)分,低于奥氮平组的(2.39±0.77)分,不良反应发生率为33.33%,低于奥氮平组的73.33%(P<0.05)。结论氨磺必利治疗儿童少年期精神分裂症的临床疗效确切,可有效改善患儿的临床症状,且用药安全性较高。
Objective To investigate the clinical efficacy of amisulpride in the treatment of childhood schizophrenia. Methods Sixty children with schizophrenia in children and adolescents admitted to psychiatric department of Jinjiang Sanatorium from August 2015 to October 2016 were randomly divided into two groups: olanzapine group and amisulpride group, 30 cases in each group . Patients in olanzapine group were treated orally with olanzapine, amisulpride was given amisulpride orally, and both groups were treated for 8 weeks continuously. The clinical efficacy, positive and negative symptoms scale (PANSS) scores (negative symptoms, positive symptoms, general psychopathology score and total score), clinical overall impression scale-total disease severity (CGI-SI) , Adverse drug reaction scale (TESS) score and adverse reaction rate. Results The total effective rate of amisulpride group was 96.67%, higher than that of olanzapine group (73.33%, P <0.05). There was no significant difference in negative symptoms, positive symptoms, general psychopathology score, total score and CGI-SI score between the two groups before intervention (P> 0.05); negative symptoms, positive symptoms, General psychopathology score and total score, CGI-SI total score was lower than olanzapine group (P <0.05). The amoxicillin group had a TESS score of (0.51 ± 0.12) points, which was lower than that of the olanzapine group (2.39 ± 0.77). The incidence of adverse reactions was 33.33% in amlodipine group, which was lower than that in olanzapine group (73.33%, P <0.05). Conclusion Amisulpride is effective in the treatment of schizophrenia in children and adolescents. It can effectively improve the clinical symptoms of children and has higher safety.